The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
Army Targets New DevSecOps Initiative to Speed Code Reviews
Gabe Chiulli said ‘Project Gatekeeper’ will use AI-assisted code evaluation and faster deployment authorizations.
8m watch -
DISA Shifts From Government-Built Cyber Tools to Commercial Tech
DOL is using artificial intelligence to modernize legacy systems, improve customer services and boost workforce efficiency.
32m listen -
NEA Leverages AI to Drive Software Development
NEA CIO Jim Tunnessen discusses AI-assisted software development, modernization, cybersecurity and responsible AI adoption across government.
7m watch -
VA OIG CIO Outlines AI Deployment, Modernization Priorities
As the VA's internal watchdog, the OIG is using AI to improve oversight while monitoring how emerging technologies are adopted across the agency.
11m listen
